Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms.
暂无分享,去创建一个
H. Cammann | C. Stephan | K. Jung | K. Miller | M. Lein | S. Değer | H. Meyer | M. Schrader | F. Friedersdorff | K. Siemßen | Hellmuth‐Alexander Meyer
[1] F. Matthews,et al. Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population , 2009, BMC urology.
[2] Kurt Miller,et al. New markers and multivariate models for prostate cancer detection. , 2009, Anticancer research.
[3] T. Ichikawa,et al. External validation and head‐to‐head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets , 2009, International journal of urology : official journal of the Japanese Urological Association.
[4] H. Cammann,et al. An artificial neural network for five different assay systems of prostate‐specific antigen in prostate cancer diagnostics , 2008, BJU international.
[5] Kazutaka Saito,et al. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. , 2008, European urology.
[6] M. Kattan,et al. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. , 2008, European urology.
[7] M. Melissari,et al. A novel nomogram to predict the probability of prostate cancer on repeat biopsy. , 2008, The Journal of urology.
[8] T. Ichikawa,et al. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL , 2008, International journal of urology : official journal of the Japanese Urological Association.
[9] Andrew J. Vickers,et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.
[10] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[11] Klaus Jung,et al. PSA and other tissue kallikreins for prostate cancer detection. , 2007, European journal of cancer.
[12] D Andrew Loblaw,et al. Assessing individual risk for prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Haese*,et al. Development and external validation of an extended 10-core biopsy nomogram. , 2007, European urology.
[14] T. H. van der Kwast,et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. , 2007, European urology.
[15] S. Loening,et al. Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies , 2007, BJU international.
[16] H. Cammann,et al. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. , 2007, Cancer letters.
[17] William J Catalona,et al. Prostate-specific antigen in clinical practice. , 2007, Cancer letters.
[18] Hartwig Huland,et al. A critical appraisal of logistic regression‐based nomograms, artificial neural networks, classification and regression‐tree models, look‐up tables and risk‐group stratification models for prostate cancer , 2007, BJU international.
[19] N. Cook. Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.
[20] E. Elkin,et al. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[21] M. Blankenstein,et al. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. , 2006, Clinical chemistry.
[22] M. Kattan,et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. , 2005, The Journal of urology.
[23] Anssi Auvinen,et al. Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screening , 2004, International journal of cancer.
[24] N. Obuchowski,et al. ROC curves in clinical chemistry: uses, misuses, and possible solutions. , 2004, Clinical chemistry.
[25] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[26] R. Molina,et al. Evaluation of a Multivariate Prostate-Specific Antigen and Percentage of Free Prostate-Specific Antigen Logistic Regression Model in the Diagnosis of Prostate Cancer , 1999, Tumor Biology.
[27] U. Stenman,et al. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. , 1999, Clinical chemistry.
[28] U. Stenman,et al. The clinical importance of free prostate-specific antigen (PSA). , 1998, Current opinion in urology.
[29] A W Partin,et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.
[30] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[31] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[32] L. Lin,et al. A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.
[33] M. Kuriyama. Prostate-Specific Antigen in Prostate Cancer , 1986, The International journal of biological markers.
[34] C. Stephan,et al. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards , 2008, Clinical chemistry and laboratory medicine.
[35] Dietmar Schnorr,et al. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. , 2006, Clinical chemistry.
[36] Title: the Use of Prostate-specific Antigen in Prostate Cancer Diagnostics , 2022 .